ABSTRACT
INTRODUCTION

Presentation of novel H1N1 (2009) influenza A is evolving as it continues to involve different
geographic locations and populations. In March 2009, a novel influenza of swine origin was nominated as new influenza A (H1N1) virus emerged in Mexico (1, 2) . As the 2009 H1N1 virus spread rapidly globally, the first new pandemic of the 21 st century occurred (3) (4) (5) . The initial epidemiology and presentation of the disease are remarkable for severe ORIGINAL ARTICLE respiratory disease, mortality in those younger than 60 years and co-morbidities (6) (7) (8) (9) .
Although the symptoms of 2009 pandemic H1N1 influenza are essentially the same as the seasonal flu, some have noted an increased frequency of gastrointestinal symptoms, including vomiting and diarrhea, and others have noted the absence of fever in a significant number of virologically-proven cases (10-11). Since no major virologic difference was found in different areas of the world, it is valuable to evaluate the presentation of H1N1 influenza in different geographic locations.
This study aimed at evaluating the clinical presentation of H1N1 (2009) influenza in a referral tertiary pulmonary care center in Iran.
MATERIALS AND METHODS
A prospective case-control study was started in November 2009. Clinical and epidemiological information of patients referred to the National Research Institute of Tuberculosis and Lung Diseases (NRITLD) with Influenza-like Illnesses (ILI) were extracted. ILI was defined as self-reported fever with cough, sore throat, or both.
All adult patients (age >15 years) with ILIs with respiratory specimens (including nasal/ throat swab, sputum or pharyngeal washing) for influenza testing by real-time reverse transcriptase polymerase chain reaction (rRT-PCR) were included in the study. Statistical Analysis: Statistical analyses were performed using the STATA software. The two-sided chi-square test was used for comparison of categorical variables, using Fisher's correction when needed. The t-test was used for comparison of the continuous variables. A two-tailed p-value of less than 0.05 was considered statistically significant.
Ethics: The study was approved by the institutional ethics committee. The most commonly reported symptoms among confirmed cases of 2009 H1N1 influenza were cough (90%), myalgia (71%), shortness of breath (67%), fever (60%), headache (54%) and chest pain (37%). Sore throat (47%), rhinorrhea/nasal congestion (33%) and otalgia (14%) were significantly more common among non-H1N1 patients (Table 2) . Although Otalgia (14% vs. 0 p-value=0.01) was more often associated with non-H1N1 infection, cough (90% vs. 72% p-value=0.03) and shortness of breath (67% vs. 47% p-value=0.02) were more often associated with laboratory-confirmed H1N1-infection. Comparative analysis of co-existing conditions and demographic factors did not reveal a significant difference between the two groups, except for chronic cardiac disease, which was more commonly found in patients with non-H1N1 infection. * P values are for the comparison of confirmed H1N1 cases and those with non-H1N1 Influenza like illnesses; missing data were excluded. †The P value was calculated using a two-sided chi-square test. ‡The P value was calculated using a two-sided Fisher's exact test because of the small number of patients (in one or both groups). ‖Patients had more than one co-morbidities. ¶ Other chronic lung diseases included idiopathic pulmonary fibrosis, bronchiectasis, pulmonary tuberculosis, recurrent pneumonia, pulmonary embolus, sarcoidosis, interstitial lung diseases. § Other chronic metabolic diseases included thyroid disorders, parathyroid disorders, and liver disorders. ‖‖Chronic immunosuppressive disorders included asplenia, adrenal disorder, chronic granulomatous disease, CVID, prednisolone intake and heart or pulmonary transplant. ¶ ¶Neurologic disorders included seizure disorder, CVA, cerebral palsy and muscular dystrophy. § § Includes diabetes, asthma, chronic obstructive pulmonary disease, cardiovascular disease and immuno-suppressive condition. Mean time interval between onset of symptoms and sampling (range)-days 3 (1-7) 3 (1-7)
* P values are for the comparison of confirmed H1N1 cases with those suffering from non-H1N1 Influenza like illnesses; missing data were excluded. †The P value was calculated using a two-sided chi-square test. ‡The P value was calculated using a two-sided Fisher's exact test because of the small number of patients (in one or both groups). ‖Patients had more than one symptom of a coexisting illness.
DISCUSSION
Since the emergence of pandemic H1N1 influenza (2009) in March 2009, lots of descriptive studies have been published in this respect all around the world (6-9). Due to the emergency of facing with the herald wave of H1N1 patients, most of those studies were descriptive and/or retrospective. Prospective case control design of the study helped evaluating the difference between H1N1 infected patients and other non H1N1 upper respiratory infections.
Although previous studies showed some differences in demographic and co-existing conditions of H1N1 infected patients, (13) (14) (15) , our results revealed limited significant differences between patients infected with H1N1 and those with other acute respiratory illnesses. We believe that the clinical presentation of H1N1 (2009) infection is largely indistinguishable from other acute respiratory illnesses. One of the most important limitations of this study was small sample size in comparison with other studies all around the world. This point should be considered in next waves of pandemic.
CONCLUSION
As the pandemic spreads worldwide and affects the majority of population, H1N1 diagnosis based on clinical presentation and demographic characteristics has become less reliable. Clinical setting of this study could be a major reason for this finding and it should be reevaluated in further studies.
